Ongoing Trial Seeks to Avert Alzheimer’s Decades Before it Strikes
An ongoing clinical trial aims to test a drug that is hoped to avert Alzheimer’s disease decades before it is expected to manifest in an individual. This study is being conducted by a team at the School of Medicine at Washington University. The drug in question, remternetug, was formulated by Eli Lilly and is intended to clear plaque from the brains of young people that have been found to have a genetic predisposition to developing Alzheimer’s disease. The study subjects are young people, some of them 18 years old, expected to develop the disease early (from their 30s onwards). In…